Search

Your search keyword '"José Valdez"' showing total 7 results
Start Over Author "José Valdez" Database Supplemental Index
7 results on '"José Valdez"'

1. The Notch Signaling Pathway and Breast Cancer: The Importance of Balance and Cellular Self-Control

Author

Germán, Saucedo-Correa, Bravo-Patiño, A., Nuñez-Anita, R.E., Javier, Oviedo-Boyso, José, Valdez-Alarcon J., and Manuel, Baizabal-Aguirre Víctor

Abstract

Background: Notch is a cell signaling pathway that is highly conserved in all metazoans and is the master responsible for cell differentiation and cross communication with other signaling pathways such as Wingless and Hedgehog. In most cancers, the Notch signaling pathway is altered, causing normal controls of vital processes such as cell cycle, differentiation and apoptosis to be compromised, leading the cell to a carcinogenic state. However, the inherent nature of the Notch signaling pathway of regulating the activation or repression of other signaling pathways related to differentiation and cell cycle has caused the strategies against breast cancer to be even more specialized and to know more efficiently the suitable method againts the disease. Methods: Different bibliographies and articles related to the Notch pathway and the biology of cancer were reviewed, especially with breast cancer, as well as the participation of other signaling pathways directly and indirectly related to the constitutive activation of the Notch pathway and relating the threads loose to create a general conceptual map of the wide effects of the malfunction of the Notch pathway in this disease so that we can understand from another point of view how this flow of information can be controlled. Results: The study of Notch signaling during more than a decade has gave us new clues to elucidate the mechanisms of their finely orchestrated molecular functioning and how this signaling path interacts with another signaling pathways in differentiation, survival, cell cycle and apoptosis. Notch Signaling is a professional in the process of differentiation and cross-talk communication with another signaling pathways, especially with the WNT and Hh pathways. The responsibility of WNT pathway is to maintain the survival and growth controls, having direct effects on the cell cycle and the Hh pathway is to maintain a state of diferentiation trought the life of the cell and the cell migration instead, cell cycle and the response to growth stimuli of angiogenesis, exacerbated characteristics of many breast cancer. Conclusion: This review highlights the complex communication network between the WNT, Hh and Notch Signaling and the therapies in the field of cancer that are not entirely effective, however, most of the therapies that are currently being developed are including the Notch Signaling as a target quite promising and is for its regulatory effect with other signaling pathways.

Published
2021
Full Text
View/download PDF

2. Bacterial sexually transmitted infections among men who have sex with men and transgender women using oral pre-exposure prophylaxis in Latin America (ImPrEP): a secondary analysis of a prospective, open-label, multicentre study

Author

Torres Silva, Mayara Secco, Torres, Thiago Silva, Coutinho, Carolina, Ismério Moreira, Ronaldo, da Costa Leite, Iuri, Cunha, Marcelo, da Costa Leite, Pedro Henrique Amparo, Cáceres, Carlos F, Vega-Ramírez, Hamid, Konda, Kelika A, Guanira, Juan, Valdez Madruga, José, Wagner Cardoso, Sandra, Benedetti, Marcos, Pimenta, Maria Cristina, Hoagland, Brenda, Grinsztejn, Beatriz, Gonçalves Veloso, Valdilea, Lacerda, Marcus Vinicius, Madruga, José Valdez, Farias, Alessandro, Lima, Josué N, Zonta, Ronaldo, Lauria, Lilian, Urbaez-Brito, J. David, d'Albuquerque, Polyana, Palombo, Claudio, Alencastro, Paulo Ricardo, Ito, Raquel Keiko de Luca, Moreira, Júlio, Benedetti, João L., Maria, Fabio V., Luz, Paula M., Freitas, Lucilene, Geraldo, Kim, Derrico, Monica, Nazer, Sandro, Kristic, Tania, Girade, Renato, Lima, Renato, Carvalho, Antônio R., Rocha, Carla, Leite, Pedro, Lessa, Marcio, Santini-Oliveira, Marilia, Bezerra, Daniel R.B., Souza, Cleo de Oliveira, Corrêa, Jacinto, Alves, Marcelo, Souza, Carolina, Portugal, Camilla, Valões, Mônica dos Santos, Mota, Gabriel Lima, Gomes, Joyce Alves, Falcão, Cynthia Ferreira Lima, Riberson, Fernanda Falcão, Melo, Luciano, Oliveira, Talita Andrade, Oliveira Júnior, Agnaldo Moreira, Fonseca, Bruna, Lannoy, Leonor Henriette, Carlos, Ludymilla Anderson Santiago, Cunha, João Paulo, Coracini, Sonia Maria de Alencastro, Rodrigues, Thiago Oliveira, Mettrau, Emília Regina Scharf, Meira, Kelly Vieira, Tavares, Heder, Valeiras, Ana Paula Nunes Viveiros, Rocha, Taiane Miyake Alves de Carvalho, Amorim, Alex, Sabadini, Patrícia, Córdoba, Luiz Gustavo, Gusmão, Caio, Faustino, Erika, Hansen, Julia Soares da Silva, Cunha, Agatha Mirian, Nishimura, Neuza Uchiyama, Santos, Jaime Eduardo Flygare Razo Prereira, Cano, Aline Barnabé, Dias, Willyam Magnum Telles, Tonhon, Magô, Rezende, Tania Regina, Gomes, Alex, Rodrigues, Eloá dos Santos, Carneiro, Maria das Dores Aires, Castilho, Alexandre, Carvalho, Mariana, Bautista-Aredondo, Sergio, Vermandere, Heleen, Diaz, Steven, Diaz-Sosa, Dulce, Guillen-Diaz-Barriga, Centli, Robles, Rebeca, Medina-Mora, Maria Elena, González, Marcela, Icelo, Ivonne Huerta, Davalos, Araczy Martinez, Castro, José Gomez, Valdez, Luis Obed Ocampo, Barajas, Fernanda Ramírez, González, Verónica Ruiz, Guadarrama, Galileo Vargas, Macías, Israel, Sánchez, Jehovani Tena, Noriega, Juan Pablo Osuna, Moheno M., H. Rodrigo, Ramírez, Jorge M. Bernal, Juarez, Víctor Dante Galicia, Vizcaíno, Gerardo, Arjona, Francisco Javier, Osco Tamayo, Cesar Vidal, Salvatierra Flores, Hector Javier, Cabrera Santa Cruz, Yovanna Margot, Moreno Aguayo, Ricardo Martín, Calvo, Gino, Vargas, Silver, Elorreaga, Oliver, Gutierrez, Ximena, Olivos, Fernando, Caviedes, Damaris, Adriazola, Daniella, Juárez, Eduardo, Mariño, Gabriela, Qquellon, Jazmin, Vasquez, Francesca, Jiron, Jean Pierre, Flores, Sonia, and Campos, Karen

Abstract

The global burden of sexually transmitted infections (STIs) poses a challenge in the context of HIV pre-exposure prophylaxis (PrEP) programmes. We aimed to explore factors associated with prevalent, incident, and recurrent STIs in men who have sex with men (MSM) and transgender women on PrEP in Brazil, Mexico, and Peru.

Published
2024
Full Text
View/download PDF

3. Recent HIV infection and annualized HIV incidence rates among sexual and gender minorities in Brazil and Peru (ImPrEP seroincidence study): a cross-sectional, multicenter study

Author

Torres, Thiago S., Teixeira, Sylvia L.M., Hoagland, Brenda, Konda, Kelika A., Derrico, Monica, Moreira, Ronaldo I., Guanira, Juan V., Benedetti, Marcos, Nazer, Sandro, Calvo, Gino M., Vargas, Silver, Benites, Carlos, Bigolin, Álisson, Alonso Neto, José Boullosa, Farias, Alessandro, Guimarães Lacerda, Marcos Vinícius, Raenck Silva, Daila Alena, Paz, Leidijany Costa, Madruga, José Valdez, Salvatierra Flores, Hector Javier, Boluarte, Ginjaylan Prada, Osco Tamayo, Cesar Vidal, Castro Antezana, Hardy Teresa, Pimenta, M. Cristina, Bórquez, Annick, Luz, Paula M., Grinsztejn, Beatriz, Szwarcwald, Celia Landmann, Cáceres, Carlos F., Veloso, Valdilea G., Kristic, Tania, Rocha, Carla, da Silva Santos, Willian, Lovreto Santana, Ana Paula, Lima, Renato, Souza, Carolina, Oliva, Talita Andrade, Valões, Mônica dos Santos, Olivetto, Jennifer, Mota, Gabriel Lima, Cano, Aline Barnabé, Trefiglio, Roberta, Coutinho, Carolina, Elorreaga, Oliver, Gutierrez, Ximena, Olivos, Fernando, Caviedes, Damaris, Adriazola, Daniella, Juárez, Eduardo, Mariño, Gabriela, Qquellon, Jazmin, Vasquez, Francesca, Jiron, Jean Pierre, Flores, Sonia, Campos, Karen, and Eguiluz, Maria

Abstract

HIV incidence estimation is critical for monitoring the HIV epidemic dynamics and the effectiveness of public health prevention interventions. We aimed to identify sexual and gender minorities (SGM) with recent HIV infections, factors associated with recent HIV infection, and to estimate annualised HIV incidence rates.

Published
2023
Full Text
View/download PDF

4. Impact of the Background Regimen on Virologic Response to Etravirine: Pooled 48-Week Analysis of DUET-1 and -2.

Author

Trottier, Benoit, Di Perri, Giovanni, Madruga, José Valdez, Peeters, Monika, Vingerhoets, Johan, Picchio, Gaston, and Woodfall, Brian J.

Abstract

Purpose: This subgroup analysis of the phase 3 DUET trials examined the impact of the background regimen on virologic response to etravirine in treatment-experienced patients. Methods: Patients received etravirine 200 mg or placebo, both twice daily with a background regimen of darunavir/ritonavir, investigator-selected nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and optional enfuvirtide. Virologic response at week 48 (viral load <50 HIV-1 RNA copies/mL) was analyzed by the number and activity of background agents. Results: Baseline phenotypic sensitivity score (PSS), enfuvirtide use, darunavir fold change in 50% effective concentration (FC), and number of baseline darunavir resistance-associated mutations (RAMs) were significant predictors of response to etravirine (P < .0001, P = .0018, P < .0001, and P = .0120, respectively). The number of active NRTIs was not a significant predictor of response (P = .0626). The highest response rates in etravirine-treated patients were associated with PSS &nvge;2, de novo enfuvirtide use, darunavir FC ≤10, ≤1 darunavir RAM, and &nvge;2 active NRTIs. Virologic response was consistently higher in etravirine-treated patients than placebo-treated patients, regardless of the activity of the background regimen. Response rates according to baseline PSS were 46% to 79% in the etravirine group versus 6% to 75% in the placebo group. Conclusion: The results of this subanalysis demonstrate higher virologic response rates with increased activity of the background regimen in both treatment groups, with the highest responses achieved in patients using &nvge;2 active agents in addition to etravirine. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

5. The Safety and Efficacy of Tenofovir DF in Combination with Lamivudine and Efavirenz Through 6 Years in Antiretroviral-Naïve HIV-1—Infected Patients.

Author

Isabel Cassetti, José Valdez Madruga, Jamal Muhamad Suleiman, Arnaldo Etzel, Lijie Zhong, Andrew Cheng, and Jeffrey Enejosa

Abstract

Background: Study 903 is a phase 3 trial with a completed 144-week, double-blind phase comparing tenofovir DF (TDF) to stavudine (d4T) in combination with lamivudine (3TC) and efavirenz (EFV) and an ongoing additional 336-week open-label extension phase. Method: Patients in Brazil, Argentina, and the Dominican Republic who completed the 144-week double-blind phase on TDF were eligible to roll over to the extension phase (weeks 144–480). Results from an interim week 288 analysis are presented. Results: Eighty-six patients (62% male, 70% white) initially randomized to the TDF arm continued treatment with TDF. At the end of the 144-week, double-blind phase, 85 of the 86 had HIV-1 RNA 3 from entry into the open-label extension to week 288. No patient discontinued due to renal adverse events. Small changes in bone mineral density at the lumbar spine and hip were seen in the first 48 weeks but were nonprogressive through 288 weeks. Mean limb fat increased from 8.0 kg at week 96 to 8.8 kg at week 288. Conclusion: Through 288 weeks, once-daily TDF+3TC+EFV demonstrated sustained antiretroviral activity with continued immunologic recovery. TDF treatment was not associated with renal adverse events or limb fat loss in antiretroviral-naïve patients. [ABSTRACT FROM AUTHOR]

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results